CC
CLDX icon

Centiva Capital’s Celldex Therapeutics CLDX Stock Holding History

Centiva Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,303
Closed -$413K – 1220
2025
Q2 		$413K Buy
+20,303
New +$395K 0.03% 1049
2023
Q4 		– Sell
-9,727
Closed -$268K – 1851
2023
Q3 		$268K Buy
+9,727
New +$305K 0.01% 1236
2018
Q4 		– Sell
-8,115
Closed -$55K – 260
2018
Q3 		$55K Sell
8,115
-4,402
-35% -$30.8K 0.03% 178
2018
Q2 		$95K Buy
+12,517
New +$167K 0.06% 84

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return